OncoTAb

Executive Summary

OncoTAb is a private US biotechnology company developing diagnostic and therapeutic solutions targeting a specific form of the MUC1 protein (tMUC1) associated with epithelial cancers. Founded in 2012 and based in Lexington, MA, the company's lead product, Agkura Personal Score, is a blood test designed to aid in the early detection of breast cancer, particularly in women with dense breast tissue where mammography has reduced sensitivity. The tMUC1 target is a well-studied tumor-associated antigen, offering a potentially high specificity for cancer detection. OncoTAb's approach addresses a significant unmet need, as dense breast tissue affects nearly half of women and increases cancer risk while limiting traditional screening effectiveness. The company has not yet disclosed total funding or valuation, but its focus on an accessible blood-based test could enable broad adoption if clinical validation is successful. However, the technology remains in development stage, and no FDA approvals or commercial products have been announced. The success of OncoTAb hinges on demonstrating clinical utility and sensitivity/specificity in upcoming studies, as well as navigating the competitive landscape of liquid biopsy and breast cancer screening.

Upcoming Catalysts (preview)

• Q2 2027Completion of Clinical Validation Study for Agkura Personal Score60% success
• Q4 2026FDA Breakthrough Device Designation or 510(k) Submission50% success
• Q3 2026Strategic Partnership or Licensing Deal with Diagnostic Company40% success